Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Quality of Life Research
Published in: Quality of Life Research 10/2016

Open Access 01-10-2016

Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials

Authors: Reija Koukakis, Francesca Gatta, Guy Hechmati, Salvatore Siena

Published in: Quality of Life Research | Issue 10/2016

Login to get access

Abstract

Purpose

Epidermal growth factor receptor inhibitors such as panitumumab are associated with characteristic skin toxicities. We summarise data from three panitumumab clinical trials to investigate the potential impact of skin toxicity on quality of life (QoL) in patients with metastatic colorectal cancer (mCRC).

Methods

The studies were randomised, open-label trials comparing standard treatment (first-line FOLFOX4 [n = 456], second-line FOLFIRI [n = 381], or best supportive care [n = 114]) with or without panitumumab in adults with KRAS/NRAS (RAS) wild-type mCRC. QoL was assessed using the EuroQoL 5-domain health state index (HSI) and overall health rating (OHR) measures. Impact of skin toxicity on changes in QoL scores was estimated using a linear mixed-effects model. Worst skin toxicity was defined in separate models as a subgroup variable or as a measure over time.

Results

Regardless of analysis method, there were no statistically significant differences between the panitumumab and comparator arms in any of the studies in terms of change in HSI or OHR scores. There were no statistically significant differences in QoL outcomes between patients with worst skin toxicity grade <3 and those with grade ≥3. In addition, there were no statistically significant differences between the panitumumab and comparator arms in subgroups of patients with worst skin toxicity of grade <3 and ≥3.

Conclusions

Addition of panitumumab to chemotherapy in RAS wild-type mCRC has no statistically significant negative effect on overall QoL, despite skin toxicity. Skin toxicity of worst grade ≥3 appeared to have similar impact on QoL as skin toxicity of grade <3.
Appendix
Available only for authorised users
Literature
1.
Yarom, N., & Jonker, D. J. (2011). The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discovery Medicine, 11, 95–105.PubMed
2.
Keating, G. M. (2010). Panitumumab: A review of its use in metastatic colorectal cancer. Drugs, 70, 1059–1078.CrossRefPubMed
3.
Douillard, J. Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., et al. (2013). Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. New England Journal of Medicine, 369, 1023–1034.CrossRefPubMed
4.
Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., et al. (2014). Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 32(Suppl. 5), Abstract #3568.
5.
Peeters, M., Oliner, K. S., Parker, A., Siena, S., Van, C. E., Huang, J., et al. (2013). Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clinical Cancer Research, 19, 1902–1912.CrossRefPubMed
6.
Patterson, S. D., Peeters, M., Siena, S., Van Cutsem, E., Humblet, Y., Van Laethem, J.-L., et al. (2013). Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408). Journal of Clinical Oncology, 13(Suppl. 15), Abstract #3617.
7.
Schwartzberg, L. S., Rivera, F., Karthaus, M., Fasola, G., Canon, J. L., Hecht, J. R., et al. (2014). PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. Journal of Clinical Oncology, 32, 2240–2247.CrossRefPubMed
8.
Amgen Europe B.V. (2015). Vectibix. EPAR product information. Breda: Amgen Europe B.V.
9.
Boyd, K. A., Briggs, A. H., Paul, J., Iveson, T., Midgely, R., Harkin, A., et al. (2011). Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: When can we stop collecting? Trials, 12(Suppl. 1), A41 (Abstract).
10.
Russi, E. G., Moretto, F., Rampino, M., Benasso, M., Bacigalupo, A., De Sanctis, V., et al. (2015). Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. Critical Reviews in Oncology/Hematology, 96, 167–182.CrossRefPubMed
11.
12.
Li, T., & Perez-Soler, R. (2009). Skin toxicities associated with epidermal growth factor receptor inhibitors. Targeted Oncology, 4, 107–119.CrossRefPubMed
13.
Montazeri, A. (2009). Quality of life data as prognostic indicators of survival in cancer patients: An overview of the literature from 1982 to 2008. Health and Quality of Life Outcomes, 7, 102.CrossRefPubMedPubMedCentral
14.
Douillard, J. Y., Rong, A., & Sidhu, R. (2013). RAS mutations in colorectal cancer. New England Journal of Medicine, 369, 2159–2160.CrossRefPubMed
15.
Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., et al. (2010). Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. Journal of Clinical Oncology, 28, 4697–4705.CrossRefPubMed
16.
Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., et al. (2014). Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 32(Suppl. 3), Abstract #LBA387.
17.
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., et al. (2007). Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology, 25, 1658–1664.CrossRefPubMed
18.
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., et al. (2010). Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 28, 4706–4713.CrossRefPubMed
19.
20.
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., et al. (2014). Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. Annals of Oncology, 25, 107–116.CrossRefPubMed
21.
Fitzmaurice, G. M., Laird, N., & Ware, J. H. (2011). Applied longitudinal analysis (2nd ed.). Hoboken: Wiley.
22.
Wang, J., Hechmati, G., Dong, J., Maglinte, G. A., Barber, B., Douillard, J.-Y. (2015). Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer. Current Medical Research and Opinion (Epub ahead of print).
23.
Odom, D., Barber, B., Bennett, L., Peeters, M., Zhao, Z., Kaye, J., et al. (2011). Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. International Journal of Colorectal Disease, 26, 173–181.CrossRefPubMed
24.
Wang, J., Zhao, Z., Barber, B., Sherrill, B., Peeters, M., & Wiezorek, J. (2011). A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer. British Journal of Cancer, 104, 1848–1853.CrossRefPubMedPubMedCentral
25.
Bennett, L., Zhao, Z., Barber, B., Zhou, X., Peeters, M., Zhang, J., et al. (2011). Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. British Journal of Cancer, 105, 1495–1502.CrossRefPubMedPubMedCentral
26.
Siena, S., Tabernero, J., Bodoky, G., Cunningham, D., Rivera, F., Ruff, P., et al. (2016). Quality of life during first−line FOLFOX4 ± panitumumab in RAS wild−type metastatic colorectal carcinoma: Results from a randomised controlled trial. ESMO Open, 1, e000041.
27.
Thaler, J., Karthaus, M., Mineur, L., Greil, R., Letocha, H., Hofheinz, R., et al. (2012). Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BioMed Central Cancer, 12, 438.PubMedPubMedCentral
28.
Láng, I., Köhne, C. H., Folprecht, G., Rougier, P., Curran, D., Hitre, E., et al. (2013). Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. European Journal of Cancer, 49, 439–448.CrossRefPubMed
29.
Romito, F., Giuliani, F., Cormio, C., Tulipani, C., Mattioli, V., & Colucci, G. (2010). Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients. Supportive Care in Cancer, 18, 329–334.CrossRefPubMed
30.
Unger, K., Niehammer, U., Hahn, A., Goerdt, S., Schumann, M., Thum, S., et al. (2013). Treatment of metastatic colorectal cancer with cetuximab: Influence on the quality of life. Zeitschrift für Gastroenterologie, 51, 733–739.CrossRefPubMed
Metadata
Title
Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials
Authors
Reija Koukakis
Francesca Gatta
Guy Hechmati
Salvatore Siena
Publication date
01-10-2016
Publisher
Springer International Publishing
Published in
Quality of Life Research / Issue 10/2016
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-016-1288-4

Other articles of this Issue 10/2016

Quality of Life Research 10/2016 Go to the issue

OriginalPaper

The relationships of posttraumatic stress disorder and depression symptoms with health-related quality of life and the role of social support among Veterans

OriginalPaper

Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy

OriginalPaper

Eating disorder features and quality of life: Does gender matter?

Brief Communication

The Swedish SCOPA-SLEEP for assessment of sleep disorders in Parkinson’s disease and healthy controls

Brief Communication

Association of physical fitness with health-related quality of life in early postmenopause

OriginalPaper

Predictors of health-related quality of life in people with a complex chronic disease including multimorbidity: a longitudinal cohort study